George V. Moukarbel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
George V. Moukarbel has a total of 138 co-authors. Here are the top co-authors by number of shared publications:
- Robert W. Ariss
Division of Cardiovascular Medicine University of Toledo Medical Center Toledo OH
8 shared publications - Salik Nazir
Division of Cardiovascular Medicine University of Toledo Medical Center Toledo OH
7 shared publications - Hani Jneid
Department of Cardiovascular Medicine, University of Texas Medical Branch, Galveston, Texas
6 shared publications Keerat Rai Ahuja
Department of Cardiology, Reading Hospital-Tower Health System, West Reading, PA
6 shared publicationsSalik Nazir
Department of Medicine, University of Toledo, Toledo, Ohio, USA
6 shared publicationsAhmed Maraey
University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA
4 shared publications
Latest Publications
- Open Access
- 3 June 2026
- Published by Elsevier in JACC: Case Reports
- p. 108732
Valve-in-Valve TAVR for Degenerated Perceval Valves
- 3 June 2026
- Published by Elsevier in JACC: Case Reports
- p. 108732
Open AccessValve-in-Valve TAVR for Degenerated Perceval Valves
- 21 June 2025
- Published by Elsevier in Respiratory Medicine
- Vol. 245, 108218
The association of obstructive sleep apnea and complications in patients following implantation of left ventricular assist devices
- 21 June 2025
- Published by Elsevier in Respiratory Medicine
- Vol. 245, 108218
The association of obstructive sleep apnea and complications in patients following implantation of left ventricular assist devices
- Open Access
- 20 May 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (10) , e038987
National Trends in Heart Failure and Acute Myocarditis–Related Death Before and During the COVID‐19 Pandemic
Background: The COVID‐19 pandemic saw a rise in cardiovascular death, likely the result of disruptions in health care delivery and the infection itself. We examine mortality trends of heart failure (HF) and acute myocarditis (AM) before and during the pandemic and identify the most affected demographic subgroups. Methods and Results: We queried the Centers for Disease Control and Prevention Wide‐Ranging Online Data for Epidemiologic Research database for deaths from HF and AM before (1999–2019) and during (2020–2021) the COVID‐19 pandemic. Age‐adjusted mortality rates were calculated and stratified by sex, race and ethnicity, and age category. Trend‐level analysis was performed using the Joinpoint Regression Program, which estimates average annual percentage change (AAPC) in age‐adjusted mortality rate with corresponding 95% CI. A total of 7 366 944 HF deaths and 33 750 AM deaths occurred during 1999 to 2021. HF and AM mortality rates downtrended before the pandemic (AAPC, −0.63 and −2.42, respectively) but reversed during the pandemic (HF AAPC, 7.91; and AM AAPC, 20.3). Overall, during the pandemic, the age‐adjusted mortality rate for both HF and AM was greater for men, non‐Hispanic Black people, and adults aged ≥65 years. The sharpest increase was observed among non‐Hispanic American Indian people (AAPC, 14.9), Hispanic people (AAPC, 9.63), and young adults (AAPC, 20.9) for HF and among women (AAPC 18.7), non‐Hispanic Black people (AAPC, 15.6), and older adults (AAPC, 23.5) for AM. Conclusions: The prepandemic downward trends of HF and AM mortality rates have reversed since 2020. Subgroups that had the greatest absolute mortality rates from both AM and HF in the pandemic years were men, non‐Hispanic Black people, and older adults (aged ≥65 years).
- 20 May 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (10) , e038987
Open AccessNational Trends in Heart Failure and Acute Myocarditis–Related Death Before and During the COVID‐19 Pandemic
Background: The COVID‐19 pandemic saw a rise in cardiovascular death, likely the result of disruptions in health care delivery and the infection itself. We examine mortality trends of heart failure (HF) and acute myocarditis (AM) before and during the pandemic and identify the most affected demographic subgroups. Methods and Results: We queried the Centers for Disease Control and Prevention Wide‐Ranging Online Data for Epidemiologic Research database for deaths from HF and AM before (1999–2019) and during (2020–2021) the COVID‐19 pandemic. Age‐adjusted mortality rates were calculated and stratified by sex, race and ethnicity, and age category. Trend‐level analysis was performed using the Joinpoint Regression Program, which estimates average annual percentage change (AAPC) in age‐adjusted mortality rate with corresponding 95% CI. A total of 7 366 944 HF deaths and 33 750 AM deaths occurred during 1999 to 2021. HF and AM mortality rates downtrended before the pandemic (AAPC, −0.63 and −2.42, respectively) but reversed during the pandemic (HF AAPC, 7.91; and AM AAPC, 20.3). Overall, during the pandemic, the age‐adjusted mortality rate for both HF and AM was greater for men, non‐Hispanic Black people, and adults aged ≥65 years. The sharpest increase was observed among non‐Hispanic American Indian people (AAPC, 14.9), Hispanic people (AAPC, 9.63), and young adults (AAPC, 20.9) for HF and among women (AAPC 18.7), non‐Hispanic Black people (AAPC, 15.6), and older adults (AAPC, 23.5) for AM. Conclusions: The prepandemic downward trends of HF and AM mortality rates have reversed since 2020. Subgroups that had the greatest absolute mortality rates from both AM and HF in the pandemic years were men, non‐Hispanic Black people, and older adults (aged ≥65 years).
- Open Access
- 1 January 2025
- Published by Tsinghua University Press in Journal of Geriatric Cardiology
- Vol. 22 (1) , 210-213
Temporal trends and contemporary outcomes of percutaneous left atrial appendage occlusion in nonagenarians
- 1 January 2025
- Published by Tsinghua University Press in Journal of Geriatric Cardiology
- Vol. 22 (1) , 210-213
Open AccessTemporal trends and contemporary outcomes of percutaneous left atrial appendage occlusion in nonagenarians
- 22 December 2024
- Published by Elsevier in Cardiovascular Revascularization Medicine
- Vol. 74, 81-82
Impact of percutaneous left atrial appendage occlusion on the severity of ischemic stroke
- 22 December 2024
- Published by Elsevier in Cardiovascular Revascularization Medicine
- Vol. 74, 81-82
Impact of percutaneous left atrial appendage occlusion on the severity of ischemic stroke
- Open Access
- 11 September 2024
- Published by Elsevier in Indian Pacing and Electrophysiology Journal
- Vol. 24 (6) , 321-329
Comparison of rhythm versus rate control of atrial fibrillation in heart failure subgroups: Systematic review and meta-analysis of randomized controlled trials
- 11 September 2024
- Published by Elsevier in Indian Pacing and Electrophysiology Journal
- Vol. 24 (6) , 321-329
Open AccessComparison of rhythm versus rate control of atrial fibrillation in heart failure subgroups: Systematic review and meta-analysis of randomized controlled trials
- 30 April 2024
- Published by SAGE Publications in Vascular and Endovascular Surgery
- Vol. 58 (6) , 680-682
Management of an Iatrogenic Pulmonary Artery Rupture via Balloon Tamponade
Pulmonary artery rupture is a rare complication of right heart catheterization characterized by a rapid clinical deterioration and high mortality rate. We present the case of an 89-year-old woman with severe symptomatic aortic stenosis who underwent cardiac catheterization prior to aortic valve replacement. The patient had acute cardiopulmonary deterioration due to pulmonary artery rupture at the time of right heart catheterization, that was successfully sealed by balloon tamponade.
- 30 April 2024
- Published by SAGE Publications in Vascular and Endovascular Surgery
- Vol. 58 (6) , 680-682
Management of an Iatrogenic Pulmonary Artery Rupture via Balloon Tamponade
Pulmonary artery rupture is a rare complication of right heart catheterization characterized by a rapid clinical deterioration and high mortality rate. We present the case of an 89-year-old woman with severe symptomatic aortic stenosis who underwent cardiac catheterization prior to aortic valve replacement. The patient had acute cardiopulmonary deterioration due to pulmonary artery rupture at the time of right heart catheterization, that was successfully sealed by balloon tamponade.
- 30 April 2024
- Published by Taylor & Francis in Expert Review of Medical Devices
- Vol. 21 (6) , 459-462
Thoracic impedance monitoring in heart failure: from theory to practice
- 30 April 2024
- Published by Taylor & Francis in Expert Review of Medical Devices
- Vol. 21 (6) , 459-462
Thoracic impedance monitoring in heart failure: from theory to practice
- 25 October 2023
- Published by Elsevier in The American Journal of Cardiology
- Vol. 210, 219-224
The Efficacy of Cardiac Myosin Inhibitors Versus Placebo in Patients With Symptomatic Hypertrophic Cardiomyopathy: A Meta-Analysis and Systematic Review
- 25 October 2023
- Published by Elsevier in The American Journal of Cardiology
- Vol. 210, 219-224
The Efficacy of Cardiac Myosin Inhibitors Versus Placebo in Patients With Symptomatic Hypertrophic Cardiomyopathy: A Meta-Analysis and Systematic Review
- 27 June 2023
- Published by Taylor & Francis in Expert Review of Medical Devices
- Vol. 20 (8) , 621-631
A profile on the CardioMEMS HF system in the management of patients with early stages of heart failure: an update
Over the past decade, there have been noteworthy advances in the evaluation and treatment of heart failure (HF). Despite improved understanding of this chronic disease, HF is still one of the leading causes of morbidity and mortality in the United States and worldwide. Decompensation and rehospitalization of HF patients remain an integral problem in disease management, with significant economic implications. Remote monitoring systems have been developed to detect HF decompensation early and address it before hospitalization. The CardioMEMS HF system is a wireless pulmonary artery (PA) monitoring system that detects changes in PA pressure and transmits data to the healthcare provider. As changes in PA pressures occur early during HF decompensation, the CardioMEMS HF system allows providers to institute timely changes in HF medical therapies to alter the course of the decompensation. The use of the CardioMEMS HF system has been shown to reduce HF hospitalization and improve quality of life. This review will focus on the available data supporting the expanded utilization of the CardioMEMS system in patients with HF. The CardioMEMS HF system is a relatively safe and cost-effective device that reduces the incidence of HF hospitalization and qualifies as intermediate-to-high value medical care.
- 27 June 2023
- Published by Taylor & Francis in Expert Review of Medical Devices
- Vol. 20 (8) , 621-631
A profile on the CardioMEMS HF system in the management of patients with early stages of heart failure: an update
Over the past decade, there have been noteworthy advances in the evaluation and treatment of heart failure (HF). Despite improved understanding of this chronic disease, HF is still one of the leading causes of morbidity and mortality in the United States and worldwide. Decompensation and rehospitalization of HF patients remain an integral problem in disease management, with significant economic implications. Remote monitoring systems have been developed to detect HF decompensation early and address it before hospitalization. The CardioMEMS HF system is a wireless pulmonary artery (PA) monitoring system that detects changes in PA pressure and transmits data to the healthcare provider. As changes in PA pressures occur early during HF decompensation, the CardioMEMS HF system allows providers to institute timely changes in HF medical therapies to alter the course of the decompensation. The use of the CardioMEMS HF system has been shown to reduce HF hospitalization and improve quality of life. This review will focus on the available data supporting the expanded utilization of the CardioMEMS system in patients with HF. The CardioMEMS HF system is a relatively safe and cost-effective device that reduces the incidence of HF hospitalization and qualifies as intermediate-to-high value medical care.